WearOptimo’s hydration Microwearable sensor will target global markets with a potential combined value of more than $20 billion. Its first product to market, currently in human trials, will be a consumer device, followed by a clinical science/medical device.
With rapid market-scaling potential, the technology has a clear and compelling commercialisation strategy, looking to first B2B sales in 2026.
Initial markets for our hydration Microwearable device are Sport, Resources and the Military. Our next-generation medical wearables will monitor key bio-signals for early warning signs of, for example, Heart Attack, Renal Failure and in Aged Care.
Future iterations of the Microwearable technology will focus on other global healthcare issues such as sepsis and immune surveillance.
The health-tech platform also provides users with SAAS reporting and monitoring, delivering insights and analysis from unique anonymised data.
WearOptimo receives investment and other support from Australian National University, Aspen Medical, family offices/high net worths, MTPConnect – BioMedTech Horizons, and state and federal governments.
For a confidential investment discussion with a member of our executive leadership team, please fill out the below Expressions of Interest and we’ll be in contact.
Investment expression of interest.
Only genuine enquiries will be actioned.
Investment expression of interest.
Only genuine enquiries will be actioned.
WearOptimo: transforming hydration monitoring with wearable technology and real-time app reporting, empowering you to stay refreshed and energised, wherever life takes you.
14 Hockings St, West End QLD 4101, Australia
Opening Hours:
Mon – Fri 9am to 5pm
Designed by Ailebo Consulting.